Temporomandibular joint (TMJ) disorders, including degenerative TMJ disease, occur primarily in women of reproductive age. Previous studies showed elevated estrogen levels in subjects with TMJ disorders relative to controls and the presence of estrogen receptors α and β (ERα and ERβ) in TMJ fibrocartilage. Additionally, estrogen-induced overexpression of specific matrix metalloproteinases (MMPs), including MMP-9 and MMP-13, in TMJ fibrocartilage is accompanied by loss of extracellular matrices. However, the contribution of ERα and ERβ in estrogen-mediated induction of MMP-9 and MMP-13 and the signaling cascade leading to the upregulation of these MMPs have not been elucidated. Here, we show that specific siRNAs and selective ER antagonists effectively block ERα or ERβ expression in primary mouse TMJ fibrochondrocytes, but that only blockage of ERα suppresses MMP-9 and MMP-13 levels induced by 17β-estradiol (E2). Overexpression of ERα but not ERβ enhances E2-induced MMP-9. Using the same loss-of-function and gain-of-function approaches, we demonstrate that E2 stimulates ERK activation through ERα and that inhibition of ERK phosphorylation reduces E2-induced MMP-9. Furthermore, we reveal that E2 promotes NF-κB and ELK-1 activation through ERα/ERK signaling and that knockdown of either one decreases the respective activity of these signaling mediators and MMP-9 expression induced by E2, indicating that both contribute to E2/ERα/ERK-mediated MMP-9 upregulation. This is supported by findings in which mutated binding sites of either NF-κB or ELK-1 in the MMP-9 promoter lead to a significant reduction of E2-stimulated promoter activity. Our findings provide novel molecular mechanisms for the understanding of E2-mediated upregulation of MMPs, having implications to pathophysiologic TMJ cartilage matrix turnover that may yield therapeutic intervention targets for TMJ disorders.
Introduction
Estrogens, which belong to the steroid family of hormones, contribute to the development and function of the female reproductive system and modulate many biological activities in cardiovascular, central nervous, and musculoskeletal systems in males and females (Eyster 2016) . The major naturally occurring estrogens are 17β-estradiol (E2), estrone, and estriol, among which E2 is the predominant one in women during the reproductive years. Within the musculoskeletal system, E2 is an important regulator of extracellular matrix (ECM) remodeling in bone and cartilage Khosla et al. 2012) . While E2 has an anabolic effect in bone, it contributes to matrix loss in cartilaginous tissue and cells of the temporomandibular joint (TMJ; Naqvi et al. 2005; Hashem et al. 2006) , which may predispose to degenerative changes in these joints. Degenerative TMJ disease is a common clinicopathologic finding within a highly prevalent spectrum of conditions known as TMJ disorders (TMJDs) that primarily afflict women during the reproductive years (Landi et al. 2005) . The early onset of degenerative TMJ disease in women during the reproductive years, as opposed to similar degenerative conditions in systemic joints that largely afflict postmenopausal women, has implicated the role of female sex hormones, particularly E2, in this disorder (Landi et al. 2005; Maixner et al. 2011) .
Most pathophysiologic functions of estrogens primarily involve estrogen receptors (ERs) α and β, whose cellular locations include the nucleus and cytoplasm (Levin and Hammes 2016) . ERα and ERβ are localized in various cartilages, including long bone articular cartilage, pubic symphysis, knee meniscus, and TMJ fibrocartilages ; Börjesson 767108J DRXXX10.1177/0022034518767108Journal of Dental Research17β-estradiol Induces MMP-9 and MMP-13 research-article2018 et al. 2013) . These receptors are more highly expressed in female than male murine and primate TMJ fibrocartilages (Milam et al. 1987; Wang et al. 2009) . While studies have shown that E2 contributes to matrix loss in fibrocartilage, it is not clear which of its receptors is responsible for ECM remodeling activities in these tissues. This distinction is important because, although the 2 receptors share 96% amino acid homology in their DNA binding domain, they have substantial differences in their ligand-binding region and activating function regions. Thus, activation of the 2 receptors can regulate different target genes and often result in varied and sometimes opposite downstream effects. ERβ was shown to repress transcriptional activity of ERα with the same ligand (Hall and McDonnell 1999) . Given these distinctions in ER functions and the coexpression of both ERs in many tissues, including TMJ fibrocartilage, it is important to determine how the presence and relative levels of both receptors affect tissue responses to E2.
E2 contributes to ECM turnover primarily through its modulation of matrix metalloproteinases (MMPs), possibly by activating 1 or more of its receptors, which trigger unknown downstream signaling pathways. The effect of E2 on tissue turnover through modulation of MMPs appears to be dose dependent and tissue/cell specific (Hashem et al. 2006; Kapila et al. 2009 ). E2 induces several MMPs, predominantly MMP-9 and MMP-13 in TMJ fibrocartilage, leading to loss of collagen and glycosaminoglycans, which is mitigated by a pan-MMP inhibitor (Naqvi et al. 2005; Hashem et al. 2006; Kapila et al. 2009 ). However, the signals that mediate E2's induction of MMPs by activation of 1 or both of its primary receptors and whether these responses occur via genomic or nongenomic actions have not been elucidated. This study was undertaken to determine the contributions of ERα and ERβ to the regulation of MMP-9 and MMP-13 by E2 and to elucidate the downstream signaling pathway involved in inducing MMP-9 in mouse TMJ fibrochondrocytes.
Materials and Methods

Animal Procedures and Cell Retrieval
All animal procedures were conducted on 12-wk-old female C57BL/6J mice (Charles River Laboratories) following approval from the Institutional Animal Care and Use Committee. TMJ fibrochondrocytes were retrieved and cultured in α-MEM supplemented with 10% fetal bovine serum, and the studies were performed as described previously (Ahmad et al. 2012) . Passage 4 to 6 fibrochondrocytes were used for each experiment.
Methods for Gain and Loss of ER Function
The fibrochondrocytes were seeded at 1.0 × 10 6 cells per 6-cm dish overnight prior to initiating gain-of-function, loss-offunction, and chemical inhibitor studies. The doses of siRNA, cDNA, and signaling inhibitors and the optimal time frame for each experiment were determined by preliminary dose-response and time-course studies. Overexpression and suppression of ER were performed by transfection of 2 μg of ERα or ERβ or control cDNA vectors and 250pM ERα or ERβ or control siRNAs (sc-29306, sc-35326, and sc-37007; Santa Cruz Biotech), respectively, as described previously (Ahmad et al. 2012 ). The transfection efficiency was about 40% to 60%, as determined by pSV-β-galactosidase vector transfection with Effectene transfection reagent (according to the manufacturer's instructions; Qiagen) in serum-free Opti-MEM media. After 6 h of incubation, the Opti-MEM was replaced with α-MEM containing 10% fetal bovine serum and maintained for 12 h. The cells were washed and maintained in serum-free medium (α-MEM with 0.2% lactalbumin hydrolysate) for 4 h, before being incubated in fresh serum-free medium with E2. After 48 h of incubation with E2, cell-conditioned media were retrieved for MMP assays and cell lysates collected for ER blots.
To determine the effect of ER signaling on MMP expression, the fibrochondrocytes were transfected with 250pM extracellular signal-regulated kinase 1/2 (ERK), E-26 transcription factor (ELK-1), or p65 nuclear factor kappa B (NF-κB; a major unit of NF-κB) or control siRNAs (sc-29859, sc-3529, sc-29411, and sc-37007; Santa Cruz Biotech) or treated with the following signaling inhibitors: 10μM U0126 (Santa Cruz Biotech), 1μM MPP for ERα, 1μM PHTPP for ERβ and 1μM ICI for ERα and ERβ (Tocris Biosciences) for 30 min prior to incubation with E2. On the basis of preliminary time-course studies, cell lysates were collected after 5 min for ERK and 10 min for ELK-1 and NF-κB assays, while the conditioned media were collected after 6 h for MMP-9 assay.
Western Blot
BCA protein assay (Pierce Biotech) and Western blots were performed as previously described (Ahmad et al. 2012) . The membranes were incubated with each of the following primary antibodies: rabbit anti-ERα or ERβ and NF-κBp65, which was anti-phosphorylated at serine-536 NF-κBp65, an activated phosphorylated form of NF-κBp65 (Mattioli et al. 2004 ) that can be identified by Western blot antibodies (Yuan et al. 2017 ; all from Santa Cruz Biotech); rabbit anti-MMP-9 (Sigma Chemicals); rabbit anti-MMP-13 (Abcam Inc.); anti-phospho-ERK (Upstate Inc.); and rabbit anti-ERK, anti-phospho-ELK-1, and ELK-1 (from Cell Signaling). This was followed by incubation with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotech) and development of the blots. Equal loading of the cell lysate was confirmed by stripping the membranes, reprobing with a rabbit anti-actin antibody (Santa Cruz Biotech), and developing the blot as described earlier. The images were quantified by ImageJ (National Institutes of Health).
Immunofluorescence
Fibrochondrocytes (5 × 10 4 cells/chamber) were seeded into slide chambers and maintained in serum-containing α-MEM until 70% confluent, fixed with 75% ethanol, permeabilized, and washed. After blocking with 1% bovine serum albumin, cells were incubated with primary antibodies specific for phospho-ERK or MMP-13 or control IgG for 3 h and washed. Following incubation with a fluorescent-labeled secondary antibody (Invitrogen) for 1 h and staining with DAPI (4′-6-diamidino-2-phenylindole), the cells were observed under a fluorescent microscope (Nikon TS100).
Mutagenesis and Luciferase-Reporter Assay
The mutants in the -1,017 MMP-9 promoter-luciferase vector (Tacon et al. 2010) were made with the site-directed mutagenesis kit (Invitrogen) and confirmed by sequencing. Wild-type (WT) or mutated NF-κB or ELK-1 sites of MMP-9 promoter-luciferase constructs were transfected with a β-galactosidase vector (Clontech) into cells seeded at 1.0 × 10 6 cells per 6-cm dish for 16 h as described. The cells were washed and maintained in α-MEM with 0.2% lactalbumin hydrolysate for 4 h before being incubated in fresh serum-free medium with E2. After 6 h of incubation with E2, cell lysates were collected and assayed for luciferase activity (Promega Corp.) and β-galactosidase activity with Tropix assay reagent (Applied Biosystems).
Statistical Analysis
Data are presented as mean ± SD fold change and analyzed by 1-way analysis of variance, followed by Sidak's multiple comparisons test, with GraphPad Prism 7.04 software. The experiments were repeated at least 3 times, and P values <0.05 were considered statistically significant.
Results
E2 Enhances MMP-9 and MMP-13 Expression via ERα but Not ERβ
ERα and ERβ are highly expressed in primary TMJ fibrochondrocytes, and their expression was suppressed by ERα-and ERβ-specific siRNAs relative to their respective controls or control siRNA (Fig. 1A, B) . With the doses of 0.1 and 0.5 ng/mL of E2 representing various serum concentrations in cycling women (Marsh et al. 2011) , we found that E2 markedly increased the expression MMP-9 (molecular weight, 92-kDa proenzyme) and MMP-13 (molecular weight, 60-kDa proenzyme; Fig. 1C, D) , with the higher concentration of E2 producing a more robust response than the lower dose. Knockdown of ERα led to a reduction in E2's induction of MMP-9 and MMP-13 (Fig. 1C, D) . In contrast, E2's induction of MMP-9 and MMP-13 was not affected by the suppression of ERβ (Fig. 1E,  F) . We further confirmed the contribution of ERα but not ERβ to the modulation of MMPs by using ERα-specific inhibitor MPP, ERβ selective inhibitor PHTTP, and pan-ER inhibitor ICI (Dehghan et al. 2015) with cells stimulated with 0.5 ng/mL of E2. None of the inhibitors had any effect on basal MMP-9 levels ( Fig. 1G, H ). MPP and ICI almost completely blocked E2-induced MMP-9 expression, while inhibition of ERβ had no effect on E2's induction of MMP-9. Similar suppressive effects of ERα inhibitors rather than the ERβ inhibitor on E2-induced MMP-13 were observed by immunofluorescence (Appendix Fig. 1) .
Next, we investigated whether ectopic expression of ERα or ERβ amplifies E2's induction of MMP-9 and MMP-13 (Fig. 2) . While overexpression of ERα or ERβ ( Fig. 2A, B) alone did not modulate MMP-9 or MMP-13 (Fig. 2C-F) , E2 increased expression of both MMPs, confirming previous observations. Importantly, ectopic expression of ERα but not ERβ amplified E2's induction of MMP-9. In contrast, E2-induced MMP-13 was not amplified by either ERα or ERβ overexpression, suggesting a likely saturation of the response under the experimental conditions. Taken together, the data from loss-of-function and gain-of-function studies provide evidence that ERα but not ERβ is essential for E2-induced MMP-9 and MMP-13 expression in TMJ fibrochondrocytes.
Estrogen Induces Expression of MMP-9 through the ERα/ERK Pathway
While E2 is known to activate ERK (Zhang et al. 2002) , it is unknown whether this signaling pathway participates in E2-induced MMP-9 expression. We found that treatment of the fibrochondrocytes with E2 for 5 minutes resulted in ERK activation (Fig. 3A-D) . Knockdown of ERα or ERβ did not influence basal phosphorylated ERK (Fig. 3A-C) . Silencing of ERα but not ERβ reduced E2-induced ERK activation. The rapidity of this response also suggests that it occurs through nongenomic activity involving ERα. The concept is supported by findings that inhibition of ERα by MPP and ICI decreased E2-induced phosphorylated ERK responses similar to those found with MEK (a direct upstream signaling molecule of ERK) inhibitor U0126 action (Fig. 3D) . Additional support for these findings is provided by experiments in which forced expression of ERα but not ERβ modestly increased E2-stimulated ERK activation (Fig. 3E, F) . Together, the data provide evidence that E2 modulates rapid phosphorylation of ERK likely via its binding to ERα. Interestingly, PHTTP or ERβ siRNA increased while ERβ cDNA decreased E2-stimulated ERK activation, suggesting that ERβ has an opposite effect to that of ERα on ERK activation.
To determine any link between ERα-induced ERK activation and MMP-9 upregulation by E2, we assayed for MMP-9 expression following knockdown of ERK. Silencing of ERK resulted in the loss of E2-mediated ERK phosphorylation and subsequently impaired E2-mediated MMP-9 expression (Fig.  3G, H) , indicating a mechanistic link between activation of ERK and increased MMP-9 level. The same pathway is involved in E2's induction of MMP-13 (Appendix Fig. 1) . Interestingly, our results also show that ERK phosphorylation is not critical to basal MMP-9 expression levels, implying that constitutively expressed MMP-9 may be regulated by other potential compensatory pathways, as demonstrated previously for MMP-2 (Kuo et al. 2006 ).
NF-κB and ELK-1 Are the Downstream Targets of the ERK Pathway for E2/ERα-Induced MMP-9 Expression
Since MMP-9 promoter contains NF-κB and ELK-1 binding sites and both are ERK downstream effectors (Eberhardt et al. 2000; Hsieh et al. 2008; Chen et al. 2016) , we next examined whether E2 increases NF-κB and ELK-1 phosphorylation and what their possible contribution is to increased MMP-9 expression. E2 did not affect NF-κBp65 and ELK-1 levels but markedly increased phosphorylation of ELK-1 (Fig. 4A, B) and NF-κBp65 (Fig. 4C, D) . Knockdown of ELK-1 and NF-κB by their respective siRNAs reduced E2-induced NF-κBp65 and ELK-1 phosphorylation. This was accompanied by the impairment of E2-induced MMP-9 expression, indicating that NF-κBp65 and ELK-1 activation is essential for E2's induction of MMP-9.
To determine whether phosphorylated NF-κBp65 and ELK-1 are downstream mediators of E2/ERα-activated ERK signaling, we treated the fibrochondrocytes with U0126 or MPP in the presence or absence of E2. Treatment with U0126 and MPP resulted in an almost complete ablation of E2-induced NF-κBp65 and ELK-1 activation, subsequently leading to a reduction of E2-mediated MMP-9 induction (Fig. 4E, F) , suggesting that NF-κBp65 and ELK-1 mediate E2/ERα/ERKinduced MMP-9 expression. Finally, to investigate whether activated NF-κB and ELK-1 are essential for MMP-9 transcription, we mutated the binding sites of NF-κB and ELK-1 in the MMP-9 promoter, which was confirmed by sequencing. Using these constructs, we showed that E2 significantly increased MMP-9 wild-type promoter activity, while the mutation of either NF-κB or ELK-1 binding sites resulted in a loss of basal and E2-induced MMP-9 promoter activity as compared with vehicle-treated control (Fig. 4G) . These findings confirmed that NF-κB and ELK-1 binding sites are essential for E2-induced MMP-9 transcription.
Discussion
We elucidated the molecular mechanism by which E2 upregulates MMP-9 and MMP-13 expression in TMJ fibrochondrocytes. MMP-9 and MMP-13 are key enzymes responsible for cartilage ECM breakdown Troeberg and Nagase 2012) , which are also upregulated in TMJDs (Leonardi et al. 2008; Loreto et al. 2013) . Our data show that E2 induces these MMPs specifically through ERα but not via ERβ. Furthermore, we show that E2's induction of MMP-9 involves the MEK/ERK/NF-κBp65 and ELK-1 signaling pathways. The rapid activation of ERK by E2/ERα interactions within a few minutes, with the fact that MMP-9 and MMP-13 promoters lack estrogen response elements (Thaler et al. 2014) , supports the concept that E2 drives MMP-9 and MMP-13 transcription through a nongenomic pathway.
E2's modulation of MMPs appears to be highly cell and tissue specific (Afratis et al. 2017) . Our findings on the upregulation of MMP-9 and MMP-13 by E2 in TMJ fibrochondrocytes concur with those of others in mesangial and endometrial (Nishi et al. 2013) cells. Interestingly, E2-mediated ECM loss, which is directly related to MMP activity, is also highly cell specific, including that in diverse types of fibrocartilaginous tissues (Hashem et al. 2006) . The basis for the divergent responses of these tissues and cell types to E2 is not well understood, but several possible reasons may explain these observations. One explanation is that since E2 can have a bimodal effect (Lindheim et al. 1993) , the use of varied E2 concentrations in these studies contributes to different MMPinductive responses of E2. Another plausible reason is the relative cellular levels of ERα versus ERβ that can affect net cell responses because ERβ is known to repress ERα transcriptional activity by the same ligand and because these receptors often have opposing downstream effects (Hall and McDonnell 1999; Tee et al. 2004 ). Indeed, our study provides evidence that activation of ERα versus ERβ has opposite effects on ERK activation, supporting previous observations of the divergent responses by E2's activation of its 2 primary receptors. We also demonstrate that ERα is specifically responsible for phosphorylation of ERK that further leads to activation of downstream targets triggering upregulation of MMP-9. This implies that despite the presence of ERα and ERβ in various cartilaginous tissues (Yamada et al. 2003; Kapila et al. 2009 ), the global effects of E2 on these tissues are likely mediated by the relative activities of both receptors that in turn are dictated by their relative expression levels.
Activation of NF-κB drives the expression of its proinflammatory target genes, such as interleukins 6 and 1β, leading to inflammation (Hoesel and Schmid 2013) . As with its modulation of MMPs, E2's effects on NF-κB activity are cell specific and partially dependent on E2 concentrations (Ghisletti et al. 2005; Hirano et al. 2007 ). Our studies not only confirm E2's stimulation of NF-κB but also demonstrate that E2 does this via ERα and MEK/ERK phosphorylation in mouse TMJ fibrochondrocytes. More important, the blockage of NF-κB and mutated NF-κB binding site in the MMP-9 promoter diminishes E2-induced MMP-9 expression, suggesting that the NF-κB site is essential for E2-induced MMP-9 transcription. Pertinent to our studies, E2-activated NF-κB is a critical mediator of TMJ inflammation (Kou et al. 2011) . Collectively, these findings suggest that NF-κB is an important convergence point for E2's proinflammatory as well as MMP-9-inductive and matrix-degradative responses in the TMJ fibrocartilage. Therefore, NF-κB could serve as a potential therapeutic target against TMJ inflammation and degeneration caused by estrogen and increased ERα levels or activity.
Because ELK-1 is a direct target of ERK and has been shown to be important for MMP-9 induction in brain astrocytes (Wang et al. 2010) , we also determined its role in E2's induction of MMP-9 in TMJ fibrochondrocytes. We found that the phosphorylation status of the ELK-1 is enhanced by E2 treatment and is inhibited with a chemical inhibitor and an ERα-specific antagonist. Thus, our systematic analysis with specific chemical inhibitors identified the requirement of ELK-1 and NF-κB multiple regulatory elements for E2-mediated induction of MMP-9 that was earlier completely unknown. These results are further substantiated by knockdown of ERK, ELK-1, and NF-κB, leading to abrogation of E2's upregulation of MMP-9. While the relative roles of NF-κB and ELK-1 in MMP-9 transcriptional activation by E2 are not known, the loss of E2-induced MMP-9 promoter activity by mutation of either NF-κB or ELK-1 binding sites suggests that both transcriptional factors are essential for E2-induced MMP-9 transcription. Further studies are warranted to identify whether the DNA fragment in the MMP-9 promoter forms a loop that is required for the binding of the 2 transcriptional factors (Tam et al. 2017) or whether the 2 factors participate together as a transcriptional complex in the MMP-9 promoter.
The pathophysiologic relevance of our findings for E2's potential role in TMJ fibrocartilage turnover and TMJDs is supported by several previous studies. First, ERs have been localized to the human TMJ (Abubaker et al. 1993) . Second, males and females with TMJDs have higher systemic levels of E2 than asymptomatic controls (Landi et al. 2005) . Finally, single-nucleotide polymorphisms in human ERα gene that upregulate ERα expression (Herrington et al. 2002) are associated with the prevalence and severity of human TMJD and pain (Stemig et al. 2015) , suggesting a possible mechanism by which ERα single-nucleotide polymorphisms may contribute to TMJDs through MMP induction and increased cartilage degradation, as shown in cells forced to overexpress ERα in our studies. In summary, we conclusively identified novel pathways showing that ERα mediates E2's induction of MMP-9 and MMP-13 in TMJ fibrochondrocytes and that induction of MMP-9 occurs through activation of ERK and NF-κB/ELK-1. Our observations and those of others on the higher levels of ERs in female versus male TMJs (Milam et al. 1987; ) may provide a possible rationale for the preponderance of TMJD in women of reproductive age. The results of this study suggest that at a molecular level, an aberrant modulation of ECM turnover by E2-induced MMP expression in TMJDs may be dependent on not only the systemic levels of E2 but also the receptor profiles in the target tissue. Understanding the signal transduction of MMP-9 and MMP-13 transcription induced by E2 will lead to better comprehension of clinical action of E2, ERα polymorphisms, and NF-κB activation in the pathogenesis of TMJDs. It is possible that manipulating differential signaling targets will yield therapeutic interventions for human TMJDs.
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N. Ahmad, W. Wang, contributed to design and data acquisition, drafted and critically revised the manuscript; S. Chen, contributed to conception, data analysis, and interpretation, drafted and critically revised the manuscript; S. Kapila, contributed to conception, design, data analysis, and interpretation, drafted and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work. . Inhibition of ELK-1 and NF-κB by their siRNAs or ERK and estrogen receptor α (ERα) with their respective inhibitors diminishes the 17β-estradiol (E2)-modulated phosphorylation of ELK-1 and/or NF-κBp65 with a corresponding decrease in matrix metalloproteinase 9 (MMP-9) induction. Additionally, mutagenesis of NF-κB or ELK-1 binding sites leads to a loss of E2-induced MMP-9 promoter activity. Western blots with quantified analysis show that (A, B) ELK-1 siRNA suppresses basal and E2-stimulated ELK-1 expression and phosphorylation and (C, D) NF-κB siRNA decreases basal and E2-stimulated expression and phosphorylation of NF-κBp65, with both resulting in the inhibition of E2's induction of MMP-9. *P < 0.05 and **P < 0.01 vs. corresponding vehicle-treated controls. ## P < 0.01 vs. C-siRNA within E2 treatment groups. (E, F) ERK inhibitor, U0126, and ERα inhibitor MPP block E2-induced phosphorylation of ELK-1 and pNF-κBp65 and induction of MMP-9. Actin was used as an internal control. *P < 0.05 and **P < 0.01 vs. corresponding vehicle-treated DMSO controls.
## P < 0.01 vs. corresponding E2 treatment DMSO controls. (G) Studies with MMP-9 promoter-luciferase (MMP-9-Luc) constructs shows E2's induction of wild-type (WT) MMP-9 promoter activity in fibrochondrocytes, which was abrogated when promoters were used with mutated NF-κB or ELK-1 binding sites in the promoter. **P < 0.01 vs. corresponding E2-treated WT MMP-9 promoter-luciferase construct. ## P < 0.01 vs. vehicle-treated wild-type MMP-9 promoter-luciferase construct. Values are presented as mean ± SD fold change.
